Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

J&J's Tibotec, Gilead create combination products for HIV

Executive Summary

Johnson & Johnson’s Tibotec Pharmaceuticals Ltd. (infectious diseases) has teamed up with Gilead Sciences Inc. (HIV/AIDS, respiratory, and cardio/metabolic diseases) to create a fixed-dose antiretroviral therapy that combines Tibotec’s Prezista (darunavir) with Gilead’s cobicistat, which increases blood levels of some HIV meds to enable once-daily dosing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register